Health Utility Gains by PASI Response Status in Chinese Patients with Moderate-to-Severe Psoriasis

Recently, the collaborative real-world study between Normin Health, Bristol Myers Squibb (BMS), Xiangya Hospital of Central South University, and Beijing Jishuitan Hospital, titled "Health utility by Psoriasis Area and Severity Index response status after biologic induction therapy in Chinese patients with moderate to severe psoriasis," was successfully published in the Journal of Comparative Effectiveness Research. The study investigated the empirical relationship between clinical response (measured by PASI) and health utility improvements following biologic induction therapy, bridging clinical trial endpoints with health economic evaluation parameters.

Key Highlights of the Study:

Study Cohort & Multi-Center Validation: Analyzed real-world follow-up data from 512 Chinese patients with moderate-to-severe plaque psoriasis receiving biologic induction therapy, with results externally validated across an independent cohort of 300 patients from five tertiary hospitals.

Major Findings:

• Dose-Response Relationship with Utility: Health utility improvements scaled directly with greater skin clearance. Patients achieving complete clearance (PASI 100) experienced the largest utility gain (mean Δ = 0.114), whereas those with low response (PASI < 50) showed minimal improvement (Δ = 0.019).

• PASI 75 as a Critical Threshold: Achieving at least a 75% improvement (PASI 75) marked a pivotal clinical tipping point for substantial health utility recovery, providing a definitive benchmark for pharmacoeconomic modeling.

• Consistent Multi-Center Generalizability: External validation across five tertiary centers demonstrated consistent response-to-utility trajectories, confirming the robustness and generalizability of the findings across routine clinical settings.

Clinical and Policy Implications:

By directly linking clinical efficacy metrics (PASI) with preference-based health utility parameters, this study delivers vital local evidence for cost-utility analyses, QALY calculations, and value-based pricing dossiers supporting biologic access and reimbursement in China.

Click here to view the full article for more details and conclusions.